Interreg Baltic Sea – Biomarker Commercializaton (BIC acronym)
Biomarkers – a constantly growing set of indicators, changes in tissues, cells or body fluids that allow predicting disease, provide a very accurate diagnosis, or adapt treatment to each individual patient to provide better and personalized treatment.
Discovering biomarkers is becoming increasingly important in both research and industry. It is expected that they will open up new possibilities for diagnosis and treatment and will contribute to economic growth.
Despite the high potential of biomarkers, there is a general lack of experience in the field of efficient placing biomarkers on the market.
All of this are why a team of nine partners from the Baltic Sea region (Biopeople / University of Copenhagen – Denmark, Tartu Biotechnology Park OÜ – Estonia, University of Turku – Finland, Turku Science Park Ltd – Finland, ScanBalt – Denmark, BioCon Valley® GmbH – Germany, University of Vilnius – Lithuania and Wroclaw Technology Park SA – Poland) under the leadership of the Danish University Hospital Ideklinikken in Aalborg in October 2017 began work on a project that aims to develop a number of facilitations for the commercialization of biomarkers: from developing guidelines to select the right biomarker for commercialization, preparation of collections of good and pitfall practices in the commercialization process, and legal aspects.
The results of the BIC project will contribute to improving the competitiveness and commercialization of biomarkers in the Baltic Sea region, which in the long term will benefit hospitals and patients by providing affordable and personalized healthcare.
BIC is the EUSBSR flagship project, which started in October 2017 and will end in September 2020. The total budget of the Biomarker Commercialization Project is EUR 2.55 million. As part of the Interreg Baltic Sea Region Program, the partners will receive a total of EUR 1.96 million in funding from the European Regional Development Fund.